Josep Tabernero, MD, PhD
Enriched profileDirector, Vall d'Hebron Institute of Oncology (VHIO); Head, Medical Oncology Department, Vall d'Hebron University Hospital (HUVH) · Vall d'Hebron Institute of Oncology (VHIO)
Josep Tabernero is Director, Vall d'Hebron Institute of Oncology (VHIO); Head, Medical Oncology Department, Vall d'Hebron University Hospital (HUVH) at Vall d'Hebron Institute of Oncology (VHIO). OpenAlex indexes 2,704 publications with 129,261 citations (h-index 148); ClinicalTrials.gov lists 19 registered studies with this person as an investigator. Clarivate lists Josep Tabernero as a Highly Cited Researcher (Clinical Medicine, 2016-2025).
Data verified 25 Aug 2026
Overview
Updated 27 Aug 2026
Josep Tabernero is Director, Vall d'Hebron Institute of Oncology (VHIO). The public record shows 2,704 publications with 129,261 citations (h-index 148), centered on Colorectal Cancer Treatments and Studies, Gastric Cancer Management and Outcomes, Lung Cancer Treatments and Mutations. It also documents an investigator role on 19 registered clinical trials.
- Most recent indexed publication: 2026 · Nature medicine
- Top research focus: Colorectal Cancer Treatments and Studies
- 19 registered trials on ClinicalTrials.gov
Generated from the cited public record · current as of 27 Aug 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 112 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 826.
Clinical & industry
trials, payments and federal fundingNot shown. No U.S. clinical registration on file.
Federally funded research awards.
Public positions
sourced statements on record- Chairman
Cancer Core Europe consortium (since 2023), pan-European alliance of comprehensive cancer centers advising on EU cancer research policy
2023verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →vhio.net ↗ - verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →vhio.net ↗
This is a research profile, built on the published record. There's no U.S. clinical registration (NPI) on file, so facts that hang off one (clinical specialty, industry payments) aren't shown. We'd rather leave a gap than guess. Why? →
Contact
An office address from a public listing. This research profile has no federal registry record to draw from.
Office address
Vall d'Hebron Institute of Oncology
Clinical trials
Updated 27 Aug 2026
Listed as an investigator on 19 registered studies on ClinicalTrials.gov. The most recent:
- Regorafenib With Tislelizumab in Patients With Selected Mismatch Repair-Proficient/Microsatellite Stable Cancers
Sponsor: Translational Research in Oncology
Industry payments
Not shown. This person has no U.S. clinical registration (NPI) on file, so we can't reliably tie industry payments reported to CMS to them. We'd rather leave a gap than guess. Why? →
NIH funding
We didn't find any NIH-funded research awards for this person in NIH RePORTER. Why? →
Congress activity
Updated 27 Aug 2026
574 congress contributions (2004–2025) across AACR, ASCO, ASTRO, ESMO, SABCS per OpenAlex. The most recent:
- Abstract 4997: The ROSALIND Study: Identifying multi-omic signatures in long-term cancer survivors for therapeutic target discovery
AACR Annual Meeting
AACR2025Co-author - Abstract CT093: Cancer Core Europe - Basket of Baskets - first results from module 1: Atezolizumab in genomically selected populations
AACR Annual Meeting
AACR2025Co-author
Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.
Publications
Updated 27 Aug 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Epigenetic fingerprints link early-onset colon and rectal cancer to pesticide exposure.
Nature medicine
Article2026 - Erdafitinib in Patients with FGFR-Altered Advanced or Metastatic Cholangiocarcinoma.
Clinical cancer research
Clinical Trial2026
Most-cited works
by citation count (OpenAlex)- 01Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine6,671 citations2013
- 02The consensus molecular subtypes of colorectal cancer5,269 citations2015
- 03The landscape of somatic copy-number alteration across human cancers4,138 citations2010
- 04
- 05
Network
Updated 27 Aug 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 27 Aug 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- LinkedIn
linkedin.com/in/josep-tabernero
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →linkedin.com ↗ - ResearchGate
researchgate.net/profile/Josep-Tabernero
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →researchgate.net ↗ - ResearchGate
researchgate.net/profile/Josep-Tabernero-2
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →researchgate.net ↗
Mentions by others
where others cite or feature them- Instagram
instagram.com/vhiobarcelona/p/C3vVFV_M6vV
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →instagram.com ↗ - Other
vhio.net/biosketch-josep-tabernero
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →vhio.net ↗ - X / Twitter
X/Twitter account @TaberneroJosep
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 27 Aug 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →vallhebron.com ↗
- PhD in Medicine and Surgery
Universitat Autònoma de Barcelona
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →vallhebron.com ↗ - verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →vallhebron.com ↗
- Executive Master in Healthcare Organization Management
ESADE Business School
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →vallhebron.com ↗ - Advanced Business Management Program
IESE Business School
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →vallhebron.com ↗
Editorial & leadership roles
journal and society appointments- Director
Vall d'Hebron Institute of Oncology (VHIO)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →vallhebron.com ↗ - Head
Medical Oncology Department, Vall d'Hebron University Hospital (HUVH)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →vallhebron.com ↗ - Head
Molecular Cancer Therapy Research Unit / Phase I clinical trials unit, Vall d'Hebron Hospital
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →vallhebron.com ↗
Highly Cited Researcher
Clarivate's annual list, by award category and year- Clinical Medicine2016201720182019202020212022202320242025verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →clarivate.com ↗
Awards & honors
honors on the public record- 2025 Barcelona Gold Medal for Scientific Merit (Medalla d'Or al Mèrit Científic)
awarded by Barcelona City Council
2025verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →barcelona.cat ↗ - verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →vhio.net ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →vhio.net ↗
Secondary affiliations
appointments beyond the home institution- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →esmo.org ↗
- Full Professor of Medicine
Universitat de Vic – Universitat Central de Catalunya (UVic-UCC)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →esmo.org ↗ - Professor of Medicine (teaching unit)
Universitat Autònoma de Barcelona, at Vall d'Hebron Hospital
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →vallhebron.com ↗
Media & interviews
press, podcasts and appearances- "Making a Difference: A Conversation With Josep Tabernero, MD, PhD"
feature interview, Oncology Times, July 2024
2024provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →journals.lww.com ↗ - "Tabernero Finds New Paths in Gastrointestinal Treatment Landscape"
feature interview, OncLive
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →onclive.com ↗ - "Josep Tabernero: It's a privilege to have been honored as a new FASCO recipient"
interview feature, OncoDaily
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →oncodaily.com ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.